STOCK TITAN

Wellington discloses 6.19% Soleno Therapeutics stake in 13G filing (NASDAQ: SLNO)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Wellington Management Group and affiliates report a significant ownership position in Soleno Therapeutics, Inc. They beneficially own 3,322,799 shares of Soleno common stock, representing 6.19% of the class as of December 31, 2025.

The Wellington entities report zero sole voting or dispositive power, with all voting and investment authority shared across group entities. The shares are owned of record by clients of various Wellington investment advisers, and no single client is reported to hold more than five percent of the class. The position is certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Soleno.

Positive

  • None.

Negative

  • None.

Insights

Wellington discloses a 6.19% institutional stake in Soleno, held for clients and not for control.

Wellington Management Group LLP and related entities report beneficial ownership of 3,322,799 Soleno Therapeutics common shares, equal to 6.19% of the company as of December 31, 2025. Voting and dispositive powers are reported as shared, with no sole authority.

The shares are owned of record by clients of multiple Wellington investment advisers, and no individual client is identified as holding over five percent of the class. The certification states the position is held in the ordinary course of business and not to change or influence control, aligning this with typical passive institutional ownership disclosure.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026

FAQ

How many Soleno Therapeutics (SLNO) shares does Wellington beneficially own?

Wellington entities beneficially own 3,322,799 shares of Soleno Therapeutics common stock. These shares are held on behalf of multiple advisory clients of Wellington investment advisers, with no single client reported as owning more than five percent of the class.

What percentage of Soleno Therapeutics (SLNO) does Wellington’s 13G filing represent?

Wellington reports beneficial ownership of 6.19% of Soleno Therapeutics’ common stock. This percentage is based on 3,322,799 shares beneficially owned as of December 31, 2025, and reflects a sizable passive institutional position in the company’s equity.

Does Wellington have sole or shared voting power over its Soleno (SLNO) shares?

Wellington reports zero sole voting power and shared voting power over up to 3,088,720 Soleno shares. It also reports zero sole dispositive power, with shared dispositive power over 3,322,799 shares, indicating all authority is exercised collectively through Wellington-related entities.

Are Wellington’s Soleno (SLNO) holdings intended to influence control of the company?

Wellington certifies the Soleno shares were acquired and are held in the ordinary course of business. The filing states they were not acquired and are not held to change or influence control of Soleno, but instead reflect passive investment activity for advisory clients.

Who legally owns the Soleno (SLNO) shares reported in Wellington’s Schedule 13G?

The securities are owned of record by clients of one or more Wellington investment advisers. Wellington Management Group LLP and its holding-company affiliates report beneficial ownership because they directly or indirectly control these advisers managing client accounts that hold Soleno shares.

As of what date are Wellington’s Soleno (SLNO) holdings measured in this 13G?

The reported holdings are measured as of December 31, 2025, which is stated as the date of the event requiring the Schedule 13G filing. The 6.19% ownership figure and 3,322,799 shares are tied specifically to that date.
Soleno Therapeutics Inc

NASDAQ:SLNO

SLNO Rankings

SLNO Latest News

SLNO Latest SEC Filings

SLNO Stock Data

2.20B
52.61M
1.79%
110.24%
14.27%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY